Genexine Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Genexine şirketinin kazançları yıllık ortalama -40.7% oranında azalırken, Biotechs sektörünün kazançları yıllık 1.6% oranında artan oldu. Gelirler yıllık ortalama 75.7% oranında azalan oldu.

Anahtar bilgiler

-40.7%

Kazanç büyüme oranı

-34.6%

EPS büyüme oranı

Biotechs Sektör Büyümesi	11.7%
Gelir büyüme oranı	-75.7%
Özkaynak getirisi	-18.9%
Net Marj	-938.8%
Son Kazanç Güncellemesi	31 Mar 2024

Yakın geçmiş performans güncellemeleri

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 19

Recent updates

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Jul 12

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Mar 14

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 19

Gelir ve Gider Dağılımı

Genexine nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

KOSDAQ:A095700 Gelir, gider ve kazançlar (KRW Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Mar 24	5,808	-54,525	13,029	26,548
31 Dec 23	4,427	-66,874	14,008	26,330
30 Sep 23	5,200	-107,828	19,182	33,093
30 Jun 23	7,224	-105,681	15,800	29,553
31 Mar 23	6,019	-96,287	16,096	26,661
31 Dec 22	16,139	-55,974	15,911	26,445
30 Sep 22	15,807	-50,558	13,330	28,044
30 Jun 22	13,662	-48,074	12,331	28,416
31 Mar 22	14,678	-52,957	10,986	31,184
31 Dec 21	36,828	-48,042	10,143	33,118
30 Sep 21	43,311	584	9,282	35,260
30 Jun 21	43,745	51,242	8,840	39,862
31 Mar 21	43,803	63,816	8,438	39,881
31 Dec 20	18,543	27,570	7,997	39,206
30 Sep 20	13,752	-4,016	8,023	38,286
30 Jun 20	17,214	-47,325	8,420	33,649
31 Mar 20	18,290	-61,230	8,928	38,480
31 Dec 19	11,303	-16,509	9,151	40,449

Kaliteli Kazançlar: A095700 şu anda kârlı değil.

Büyüyen Kar Marjı: A095700 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: A095700 kârlı değildir ve zararlar son 5 yılda yılda 40.7% oranında artmıştır.

Büyüme Hızlandırma: A095700 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: A095700 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -1.3% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: A095700 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -18.92% ) sahiptir.

Genexine Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2023 earnings released: ₩1,652 loss per share (vs ₩1,715 loss in FY 2022)

First quarter 2021 earnings released: EPS ₩861 (vs ₩628 loss in 1Q 2020)

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Recent updates

New minor risk - Shareholder dilution

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Full year 2023 earnings released: ₩1,652 loss per share (vs ₩1,715 loss in FY 2022)

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

New minor risk - Revenue size

New minor risk - Share price stability

Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority (BPOM)

Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study

Ajinomoto Co., Inc. (TSE:2802) agreed to acquire remaining 25% stake in Ajinomoto Genexine Co., Ltd from Genexine, Inc. (KOSDAQ:A095700) for KRW 19.3 billion.

Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for Its Promising DNA Vaccine for Advanced Cervical Cancer

Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

Genexine, Inc. has completed a Follow-on Equity Offering in the amount of KRW 82.044713 billion.

No independent directors

Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

First quarter 2021 earnings released: EPS ₩861 (vs ₩628 loss in 1Q 2020)

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Genexine, Inc., Annual General Meeting, Mar 29, 2021

New 90-day low: ₩94,300

Turret Capital Management Signs A Definitive License Agreement with Genexine, Inc

New 90-day low: ₩103,600

Genexine, Inc. and NeoimmuneTech, Inc. Releases Data for Their Phase 1B/2 Study of Gx-I7/Nt-I7 and Keytruda® in Patients with Triple-Negative Breast Cancer

New 90-day low: ₩104,000

New 90-day low: ₩109,500

Genexine, Inc. announced that it has received KRW 3.29761 billion in funding from Handok, Inc.

New 90-day high - ₩132,000

New 90-day high - ₩130,600

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin